HRP20050308A2 - Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists - Google Patents

Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists

Info

Publication number
HRP20050308A2
HRP20050308A2 HR20050308A HRP20050308A HRP20050308A2 HR P20050308 A2 HRP20050308 A2 HR P20050308A2 HR 20050308 A HR20050308 A HR 20050308A HR P20050308 A HRP20050308 A HR P20050308A HR P20050308 A2 HRP20050308 A2 HR P20050308A2
Authority
HR
Croatia
Prior art keywords
chirale
oxazole
acid derivatives
ppar agonists
arylpropionic acid
Prior art date
Application number
HR20050308A
Other languages
English (en)
Croatian (hr)
Inventor
Binggeli Alfred
Boehringer Markus
Grether Uwe
Hilpert Hans
Hirth Georges
Maerki Hans-Peter
Meyer Markus
Mohr Peter
Ricklin Fabienne
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20050308A2 publication Critical patent/HRP20050308A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20050308A 2002-10-07 2003-10-06 Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists HRP20050308A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02022286 2002-10-07
PCT/EP2003/011030 WO2004031162A1 (en) 2002-10-07 2003-10-06 Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists

Publications (1)

Publication Number Publication Date
HRP20050308A2 true HRP20050308A2 (en) 2006-07-31

Family

ID=32049977

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050308A HRP20050308A2 (en) 2002-10-07 2003-10-06 Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists

Country Status (31)

Country Link
US (2) US6969725B2 (de)
EP (1) EP1551814B1 (de)
JP (1) JP4414886B2 (de)
KR (1) KR100623819B1 (de)
CN (1) CN100415727C (de)
AR (1) AR041481A1 (de)
AT (1) ATE402153T1 (de)
AU (1) AU2003273949B2 (de)
BR (1) BR0315114A (de)
CA (1) CA2499721C (de)
CO (1) CO5540385A2 (de)
DE (1) DE60322408D1 (de)
DK (1) DK1551814T3 (de)
ES (1) ES2311110T3 (de)
GT (1) GT200300218A (de)
HR (1) HRP20050308A2 (de)
IL (1) IL167250A (de)
MX (1) MXPA05003392A (de)
MY (1) MY143576A (de)
NO (1) NO330171B1 (de)
NZ (1) NZ538465A (de)
PA (1) PA8584501A1 (de)
PE (1) PE20040591A1 (de)
PL (1) PL208743B1 (de)
PT (1) PT1551814E (de)
RU (1) RU2303593C2 (de)
SI (1) SI1551814T1 (de)
TW (1) TWI343915B (de)
UY (1) UY28006A1 (de)
WO (1) WO2004031162A1 (de)
ZA (1) ZA200502664B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2506112A1 (en) * 2002-11-15 2004-06-03 Cadila Healthcare Limited Substituted aralkyl derivatives
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
KR20080082541A (ko) * 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
CN101805336B (zh) * 2009-02-13 2012-05-30 天津药物研究院 一类含色氨酸和异恶唑骨架的化合物、其制备方法和用途
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
CN1235887C (zh) 1998-03-30 2006-01-11 日本烟草产业株式会社 噁唑基乙醇衍生物的制备方法
HUP0103714A3 (en) * 1998-05-11 2003-05-28 Takeda Pharmaceutical Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
RU2219172C2 (ru) * 1999-04-06 2003-12-20 Санкио Компани, Лимитед α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DE10031657A1 (de) 2000-06-29 2002-01-24 Siemens Ag Hochfrequenz-Bauelement
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
DE60211891T2 (de) 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar

Also Published As

Publication number Publication date
US6969725B2 (en) 2005-11-29
PT1551814E (pt) 2008-09-22
GT200300218A (es) 2004-05-24
US20040116487A1 (en) 2004-06-17
ZA200502664B (en) 2006-02-22
CA2499721C (en) 2011-03-15
JP4414886B2 (ja) 2010-02-10
PL376363A1 (en) 2005-12-27
DK1551814T3 (da) 2008-10-27
PA8584501A1 (es) 2004-05-21
KR100623819B1 (ko) 2006-09-13
JP2006504709A (ja) 2006-02-09
BR0315114A (pt) 2005-08-16
EP1551814B1 (de) 2008-07-23
DE60322408D1 (de) 2008-09-04
AU2003273949B2 (en) 2007-04-05
NO20051011L (no) 2005-05-02
AU2003273949A1 (en) 2004-04-23
RU2005114373A (ru) 2006-05-10
SI1551814T1 (sl) 2008-10-31
TW200409761A (en) 2004-06-16
UY28006A1 (es) 2004-04-30
RU2303593C2 (ru) 2007-07-27
NO330171B1 (no) 2011-02-28
MXPA05003392A (es) 2005-06-22
US7348349B2 (en) 2008-03-25
HK1083339A1 (en) 2006-06-30
CN1703406A (zh) 2005-11-30
US20050267180A1 (en) 2005-12-01
ES2311110T3 (es) 2009-02-01
MY143576A (en) 2011-05-31
PL208743B1 (pl) 2011-06-30
CO5540385A2 (es) 2005-07-29
EP1551814A1 (de) 2005-07-13
PE20040591A1 (es) 2004-08-30
TWI343915B (en) 2011-06-21
NZ538465A (en) 2007-08-31
WO2004031162A1 (en) 2004-04-15
AR041481A1 (es) 2005-05-18
KR20050055750A (ko) 2005-06-13
IL167250A (en) 2010-12-30
CA2499721A1 (en) 2004-04-15
ATE402153T1 (de) 2008-08-15
CN100415727C (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
EP1689406A4 (de) Heterocyclische inhibitoren von mek und verfahren zu deren anwendung
YU69902A (sh) Novi derivati piperazina
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
NO20053627L (no) Malonamidderivater som gamma-sekretase inhibitorer
YU18101A (sh) 4-amino supstituisani-2-supstituisani-1,2,3,4- tetrahidrohinolini kao inhibitori cetp
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
DOP2004001052A (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
DK0772600T3 (da) 1,2-substituerede imidazolylforbindelser til behandling af inflammation
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
BR9509212A (pt) Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DE69505542D1 (de) 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
ATE266623T1 (de) Caspase inhibitoren und deren verwendung
DE60141520D1 (de) 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
FI964772A0 (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
HRP20050158A2 (en) Novel 2-arylthiazole compounds as pparalpha and ppargama agonists

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110928

Year of fee payment: 9

OBST Application withdrawn